Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 84,34 € (-3,49%). La mediana è 89,33 € (+2,22%).
| Acquista |
11 |
| Mantieni |
0 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Kiniksa significantly increases ARCALYST sales and advances IL-1 pipeline
Kiniksa reported Q2 net sales of about $243 million for ARCALYST, an increase of $29 million versus the prior quarter and the strongest growth since market launch. The company says it is profitable and is targeting a positive annual cash‑flow trajectory. KPL-387 has entered the Phase III study of the PASTEURAL program with the goal of once‑monthly dosing and a possible launch in 2028–2029; KPL-1161 is being developed as a potential quarterly option. Kiniksa sees additional market potential in recurrent pericarditis and highlights a growing prescriber base and solid payer support. » Altro su de.investing.com
Kiniksa Pharmaceuticals reaches record high at $64.85
Kiniksa Pharmaceuticals’ stock rose to a record high of $64.85 and is up 130.88% year-to-date. The company has a market capitalization of $4.96 billion and reported revenue growth of 57% in the past year. For Q1 2026, Kiniksa reported earnings per share of $0.27 (expectation $0.21) and revenue of $214.3 million (expectation $207.1 million). InvestingPro rates the stock close to its fair value but notes an overbought RSI. » Altro su de.investing.com
Kiniksa raises guidance after strong Q1 – ARCALYST revenue grows 56%
Kiniksa reported ARCALYST revenue of US$214.3 million in Q1 2026 (up 56% year‑on‑year) and EPS of $0.27, beating expectations. The company raised its full-year guidance for net product sales of ARCALYST to US$930–945 million (previously US$900–920 million). Net income, operating margin and cash increased substantially; management highlighted market expansion, direct‑to‑consumer marketing and ongoing clinical programs KPL‑387 and KPL‑1161. The stock rose sharply after the results and is approaching its 52‑week high. » Altro su de.investing.com
Kiniksa reports strong Q1 2026 thanks to ARCALYST and raises full-year guidance
Kiniksa recorded significant revenue growth from ARCALYST in Q1 2026 to $214.3 million (+56% y/y) and raised its full-year guidance to $930–945 million. Net income and operating income increased markedly; earnings per share were $0.27, beating expectations. The company broadened its prescriber base and now addresses patients with a first relapse; commercial momentum and pipeline candidates KPL-387 and KPL-1161 are expected to support further growth. Liquidity and the balance sheet improved, while higher revenue-linked collaboration costs and rising R&D spending temper the margin profile. » Altro su de.investing.com
Kiniksa Pharmaceuticals reaches profitability after strong Arcalyst growth, stock falls premarket
Kiniksa Pharmaceuticals reported Q4 2025 revenue of $202.1 million (+65% versus Q4 2024) and a net profit of $14.2 million after a net loss in the year‑ago quarter. For full-year 2025 the company posted revenue of $677.6 million (+62%) and a net income of $59 million. The strong performance was driven mainly by Arcalyst; Kiniksa has $414.1 million in cash and plans to expand the IL‑1 franchise and advance KPL‑387. Despite the results, the stock fell 6.44% premarket to $44.34. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 252,47 Mln | 63,82% |
| Utile lordo | 134,53 Mln | 62,32% |
| Utile netto | 41,8 Mln | 166,08% |
| EBITDA | 52,57 Mln | 124,01% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 6,86 Mld € |
Numero di azioni | 78,57 Mln |
Massimo/minimo a 52 settimane | 90,06 € - 33,57 € |
| Dividendi | No |
Beta | 0,08 |
Rapporto P/E | 67,36 |
Rapporto PEG | 0,35 |
Rapporto P/B | 10,61 |
Rapporto P/S | 8,00 |
Profilo aziendale
Kiniksa Pharmaceuticals, Ltd., un'azienda biofarmaceutica, si concentra sulla scoperta, l'acquisizione, lo sviluppo e la commercializzazione di farmaci terapeutici per pazienti affetti da malattie debilitanti con significative esigenze mediche insoddisfatte in tutto il mondo. I suoi candidati farmaci includono ARCALYST, un inibitore di interleuchina-1alfa e interleuchina-1beta, per il trattamento della pericardite recidivante, una malattia cardiovascolare infiammatoria; Mavrilimumab, un inibitore a base di anticorpi monoclonali che ha completato le sperimentazioni cliniche di Fase II per il trattamento dell'arterite a cellule giganti; Vixarelimab, un anticorpo monoclonale, attualmente in sperimentazione clinica di Fase 2a per il trattamento del prurigo nodulare, una condizione infiammatoria cronica della pelle; e KPL-404, un inibitore a base di anticorpi monoclonali dell'interazione CD40-CD154, un segnale di co-stimolazione delle cellule T fondamentale per la maturazione delle cellule B, il cambio di classe delle immunoglobuline e la risposta immunitaria di tipo 1. Kiniksa Pharmaceuticals, Ltd. è stata costituita nel 2015 e ha sede a Hamilton, nelle Bermuda.
| Nome | KINIKSA A BE-,000273235 |
| CEO | Sanj K. Patel |
| Sede centrale | London,
gl Bermuda |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 25/05/2018 |
| Dipendenti | 366 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | KNSA |